Nevertheless, the native selectivity profile makes Cbok7 an outstanding candidate for selective inhibition of Kv1.2 and it can be further exploited to treat gain-of-function associated Kv1.2 channelopathies. This evidence concerns the gene KCNA2 and channelopathy.